NYSE:EVHC - Envision Healthcare Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$44.96 -0.07 (-0.16 %)
(As of 08/19/2018 05:26 AM ET)
Previous Close$44.96
Today's Range$44.91 - $45.25
52-Week Range$23.77 - $52.72
Volume1.46 million shs
Average Volume3.22 million shs
Market Capitalization$5.41 billion
P/E Ratio18.13
Dividend YieldN/A
Envision Healthcare logoEnvision Healthcare Corporation, through its subsidiaries, provides various healthcare services in the United States. The company operates through two segments, Physician Services and Ambulatory Services. As of December 31, 2017, its physician-led services encompassed providers at approximately 1,800 clinical departments at healthcare facilities in 45 states and the District of Columbia that include emergency department and hospitalist, anesthesiology, radiology/tele-radiology, and children's services. The company also offers ambulatory surgical centers (ASCs) services that provide surgical procedures across multiple specialties, including gastroenterology, ophthalmology, orthopedics, and others. It operated 264 ASCs in 35 states and the District of Columbia. In addition, it provides surgery services, such as management, oversight, and surgeon staffing for trauma surgery services; offers direct patient care and care coordination by clinicians outside the acute care setting through physician-led post-acute care services; and operates office-based medical practices that primarily focus on women's health, as well as provides physician staffing and related management services. Further, it offers medical transportation services in 41 states and the District of Columbia. The company offers its clinical solutions for health systems, payors, providers, and patients. Envision Healthcare Corporation was founded in 1992 and is based in Nashville, Tennessee.

Receive EVHC News and Ratings via Email

Sign-up to receive the latest news and ratings for EVHC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Offices & clinics of medical doctors


Debt-to-Equity Ratio0.87
Current Ratio2.44
Quick Ratio2.42


Trailing P/E Ratio18.13
Forward P/E Ratio13.15
P/E Growth1.14

Sales & Book Value

Annual Sales$12.18 billion
Price / Sales0.45
Cash Flow$6.2444 per share
Price / Cash7.20
Book Value$59.24 per share
Price / Book0.76


EPS (Most Recent Fiscal Year)$2.48
Net Income$-228,000,000.00
Net Margins-18.81%
Return on Equity5.04%
Return on Assets2.20%


Outstanding Shares121,390,000
Market Cap$5.41 billion

Envision Healthcare (NYSE:EVHC) Frequently Asked Questions

What is Envision Healthcare's stock symbol?

Envision Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVHC."

How will Envision Healthcare's stock buyback program work?

Envision Healthcare announced that its board has authorized a share buyback program on Tuesday, September 19th 2017, which allows the company to repurchase $250,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 4.5% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board of directors believes its shares are undervalued.

How were Envision Healthcare's earnings last quarter?

Envision Healthcare Corp (NYSE:EVHC) released its quarterly earnings results on Monday, August, 6th. The company reported $0.92 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.87 by $0.05. The firm had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.10 billion. Envision Healthcare had a negative net margin of 18.81% and a positive return on equity of 5.04%. Envision Healthcare's revenue was up 6.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.85 EPS. View Envision Healthcare's Earnings History.

When is Envision Healthcare's next earnings date?

Envision Healthcare is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Envision Healthcare.

What price target have analysts set for EVHC?

16 brokerages have issued twelve-month price objectives for Envision Healthcare's stock. Their forecasts range from $31.00 to $51.00. On average, they expect Envision Healthcare's stock price to reach $41.70 in the next twelve months. This suggests that the stock has a possible downside of 7.3%. View Analyst Price Targets for Envision Healthcare.

What is the consensus analysts' recommendation for Envision Healthcare?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Envision Healthcare in the last year. There are currently 12 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Envision Healthcare.

What are Wall Street analysts saying about Envision Healthcare stock?

Here are some recent quotes from research analysts about Envision Healthcare stock:
  • 1. Cantor Fitzgerald analysts commented, ". We are reiterating our Neutral rating, but adjusting our 2018 and 2019 estimates to reflect 2Q18 results, and raising our price target to $46 from $40, to reflect KKR’s pending acquisition of EVHC. The company’s progress towards cost cutting showed in 2Q18 as adjusted EBITDA was higher than our estimate, despite flat volumes and lower than expected revenue, on lower supply costs and other operating expenses. The $9.9 billion (including $4.4 billion of debt) deal is expected to close in 4Q18 and represents a multiple of 10x our 2018 adjusted EBITDA estimate." (8/10/2018)
  • 2. According to Zacks Investment Research, "Envision Healthcare’s shares have outperformed the industry’s gain year to date. Given its strong fundamentals, the shares of the company are expected to continue the bull run in the upcoming quarters. It has witnessed its 2018 and 2019 estimates move upward over the past 90 days.  The company’s impressive revenue growth was driven by the company’s Physicians Services segment. It is optimistic about the physician services market, witnessing consolidation. Also, the divestiture of its AMR business will help the company focus on its core operations. The company’s strategic acquisitions to bring inorganic growth has also been a driving force. However, the company suffers high leverage, leading to increased interest ratio. Its operating expense is exceeding the revenue growth and exerting pressure on the operating margins." (7/10/2018)
  • 3. Canaccord Genuity analysts commented, "We reiterate our BUY rating and raise our PT to $46 based on an improving financial outlook given restructuring and easing utilization headwinds. The company characterized guidance as highly visible and not heroic. As such, we recommend continued exposure as utilization headwinds dissipate and the operational improvement plan takes hold. Key positive: High visibility into 2018 guidance: The low-end of 2018 adj-EBITDA of $960M is 87% in hand when annualizing 4Q’17. M&A from 2017 and 2018 should contribute an incremental $10-$15M and $20-$30M, respectively, bringing visibility up to 92% coverage at the low-end. Organic growth and further expense benefits from operational improvements would be the last leg in getting to guidance. Key negative: Consolidated organic growth rate lowered to 2-5% (was 3-6%) taking into account a softer utilization environment." (2/28/2018)

Are investors shorting Envision Healthcare?

Envision Healthcare saw a decrease in short interest in the month of July. As of July 13th, there was short interest totalling 15,690,958 shares, a decrease of 14.8% from the June 29th total of 18,406,285 shares. Based on an average daily trading volume, of 2,577,391 shares, the short-interest ratio is presently 6.1 days. Currently, 13.2% of the shares of the company are sold short. View Envision Healthcare's Current Options Chain.

Who are some of Envision Healthcare's key competitors?

Who are Envision Healthcare's key executives?

Envision Healthcare's management team includes the folowing people:
  • Mr. Christopher A. Holden, CEO, Pres & Director (Age 54)
  • Ms. Claire M. Gulmi, Advisor (Age 64)
  • Mr. Kevin D. Eastridge, Exec. VP & CFO (Age 53)
  • Mr. Karey Lynn Witty, Exec. VP & COO (Age 53)
  • Mr. Kenneth E Zongor, Sr. VP & Chief Accounting Officer (Age 42)

Has Envision Healthcare been receiving favorable news coverage?

Media coverage about EVHC stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Envision Healthcare earned a coverage optimism score of 0.09 on Accern's scale. They also assigned press coverage about the company an impact score of 46.48 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Envision Healthcare.

Who are Envision Healthcare's major shareholders?

Envision Healthcare's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (2.09%), Dimensional Fund Advisors LP (1.90%), Alpine Associates Management Inc. (1.60%), Boston Partners (0.86%), Bank of New York Mellon Corp (0.74%) and Schwab Charles Investment Management Inc. (0.66%). Company insiders that own Envision Healthcare stock include John Thomas Gawaluck and Robert Jon Coward. View Institutional Ownership Trends for Envision Healthcare.

Which institutional investors are selling Envision Healthcare stock?

EVHC stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Bank of Nova Scotia, Aristotle Capital Boston LLC, Swiss National Bank, Bank of Montreal Can, Douglas Lane & Associates LLC, Legal & General Group Plc and Dimensional Fund Advisors LP. View Insider Buying and Selling for Envision Healthcare.

Which institutional investors are buying Envision Healthcare stock?

EVHC stock was acquired by a variety of institutional investors in the last quarter, including Alpine Associates Management Inc., Cowen Inc., FMR LLC, Toronto Dominion Bank, Chicago Capital Management LLC, Water Island Capital LLC, Omni Partners LLP and LMR Partners LLP. View Insider Buying and Selling for Envision Healthcare.

How do I buy shares of Envision Healthcare?

Shares of EVHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Envision Healthcare's stock price today?

One share of EVHC stock can currently be purchased for approximately $44.96.

How big of a company is Envision Healthcare?

Envision Healthcare has a market capitalization of $5.41 billion and generates $12.18 billion in revenue each year. The company earns $-228,000,000.00 in net income (profit) each year or $2.48 on an earnings per share basis. Envision Healthcare employs 69,300 workers across the globe.

How can I contact Envision Healthcare?

Envision Healthcare's mailing address is 1A BURTON HILLS BOULEVARD, NASHVILLE TN, 37215. The company can be reached via phone at 615-665-1283 or via email at [email protected]

MarketBeat Community Rating for Envision Healthcare (NYSE EVHC)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  500 (Vote Outperform)
Underperform Votes:  284 (Vote Underperform)
Total Votes:  784
MarketBeat's community ratings are surveys of what our community members think about Envision Healthcare and other stocks. Vote "Outperform" if you believe EVHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Featured Article: Leveraged Buyout (LBO)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.